Amprologix Limited, a University of Plymouth spinout company, has won a £1.2 million contract from the Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.
Amprologix was established in 2018 to commercialise the work of Mathew Upton, Professor of Medical Microbiology in the University’s Institute of Translational and Stratified Medicine (ITSMed). Upton will present the company in the start-up pitch of this years AMR conference in Berlin.
The company has now been awarded funding by the Small Business Research Initiative (SBRI), part of Innovate UK, to make its epidermicin NI01 antibiotic ready for the first phase of human clinical trials during early 2021. Amprologix’s first product is expected to be a nasal cream containing epidermicin NI01 to prevent MRSA infections. Epidermicin is derived from bacteria found on human skin, and work conducted to date shows a single dose to be as effective as six doses of the current gold standard treatment in a relevant model of MRSA infection.